ArticleCells2021
In Vitro Cell Toxicity and Intracellular Uptake of Doxorubicin Exposed as a Solution or Liposomes: Implications for Treatment of Hepatocellular Carcinoma.
Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 67 citations in OpenAlex.
- Amphiphilic Lipid-Polymer Triblock Architectures as Nanocarriers for Therapeutic Delivery.ACS omega · 2026Article
- Doxorubicin-Induced Cytotoxicity in Adipose-Derived Stem Cells Is Associated With Altered SAPK/JNK Signaling.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- 3D HepG2 spheroid model exhibits drug-specific response profiles validating their application in therapeutic screening.In vitro cellular & developmental biology. Animal · 2026Article
- Liposomal glytrexate formulation: improving antitumour efficacy and minimizing toxicity in breast cancer therapy.International journal of pharmaceutics: X · 2025Article
- Edaravone attenuates doxorubicin-induced oral mucosal injury via modulation of oxidative stress, inflammatory signaling, and the SIRT1/TLR4/NF-kB/ACE2 axis in rats.BMC oral health · 2025Article
- Redox-Responsive π-Conjugated Prodrug Nanoassemblies for Cancer Chemotherapy.Pharmaceutics · 2025Article
- Dox-HCl and miR-145 co-delivery through CD44-targeted PEGylated liposomes inhibit Breast CancerNanomedicine (London, England) · 2025Article
- Safe and Efficient Intracellular Release of SN38 via Lysosomal-Responsive SN38-G Loaded Liposomes.ACS applied bio materials · 2025Article
- Distinct In Vitro Effects of Liposomal and Nanostructured Lipid Nanoformulations with Entrapped Acidic and Neutral Doxorubicin on B16-F10 Melanoma and Walker 256 Carcinoma Cells.Pharmaceutics · 2025Article
- Combination Treatment with Free Doxorubicin and Inductive Moderate Hyperthermia for Sarcoma Saos-2 Cells.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Enhancing Intracellular Uptake of Ivermectin through Liposomal Encapsulation.AAPS PharmSciTech · 2025Article
- Therapeutic Effects of Crocin Nanoparticles Alone or in Combination with Doxorubicin against Hepatocellular CarcinomaAnti-cancer agents in medicinal chemistry · 2025Article
- Recombinant expression, downstream optimization, and therapeutic evaluation of recombinant human interleukin-37 for cancer therapy.Biotechnology letters · 2024Article
- In vitro assessment of nanomedicines' propensity to cause palmar-plantar erythrodysesthesia: A Doxil vs. doxorubicin case study.Nanomedicine : nanotechnology, biology, and medicine · 2024Article
- 4-Hexylresorcinol Loaded Solid Lipid Nanoparticles for Enhancing Anticancer Activity.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Raptinal: a powerful tool for rapid induction of apoptotic cell death.Cell death discovery · 2024Review
- Article
- Quantitative imaging of doxorubicin diffusion and cellular uptake in biomimetic gels with human liver tumor cells.Drug delivery and translational research · 2024Article
- Combination Treatment with Liposomal Doxorubicin and Inductive Moderate Hyperthermia for Sarcoma Saos-2 Cells.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Exploring doxorubicin transport in 2D and 3D models of MDA-MB-231 sublines: impact of hypoxia and cellular heterogeneity on doxorubicin accumulation in cells.American journal of cancer research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Cytostatic effects of doxorubicin in clinically applied doses are often inadequate and limited by systemic toxicity. The main objective of this in vitro study was to determine the anti-tumoral effect (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.